@article{a96e7f683aff4f33ab358a3db71ad22a,
title = "Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party",
abstract = "The best therapeutic approach for primary plasma cell leukemia (PPCL) remains unknown so far. In very limited studies, the poor clinical outcome of this aggressive variant of multiple myeloma seemed to be ameliorated by the use of the proteasome inhibitor bortezomib. Aiming to provide more consolidated data, this multicenter retrospective survey focused on unselected and previously untreated PPCL patients who had received bortezomib as frontline therapy.",
keywords = "plasmacell leukemia, plasmacell leukemia",
author = "Livio Pagano and Mansueto, {Giovanna Rosaria} and Antonella Venditti and Ferdinando Ferrara and G D'Arena and Cg Valentini and G Pietrantuono and R Guariglia and Mc Martorelli and O Villani and D Onofrillo and A Falcone and G Specchia and G Semenzato and {Di Renzo}, N and L Mastrullo and A Palumbo and P. Musto",
year = "2012",
doi = "10.1093/annonc/mdr480",
language = "English",
volume = "23",
pages = "1499--1502",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Attuale:OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD, ENGLAND, OX2 6DP Kluwer Academic Publishers:Journals Department, PO Box 322, 3300 AH Dordrecht Netherlands:011 31 78 6576050, EMAIL: frontoffice@wkap.nl, kluweronline@wkap.nl, INTERNET: http://www.kluwerlaw.com, Fax: 011 31 78 6576254",
}